ArticleThe AAPS journal2007
Preparation and ocular pharmacokinetics of ganciclovir liposomes.
Article in The AAPS journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 102 citations in OpenAlex.
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Nanovesicles as Potential Carriers for Delivery of Antiviral Drugs: A Comprehensive Review.Current drug delivery · 2025Review
- Ciprofloxacin hydrochloride-loaded ocular silk fibroin liposomes: Formulation, characterisation,Heliyon · 2024Article
- Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.Drug delivery and translational research · 2024Article
- Design and Development of Ophthalmic Liposomes from the QbD Perspective.Current pharmaceutical design · 2024Review
- Role of mucoadhesive agent in ocular delivery of ganciclovir microemulsion: cytotoxicity evaluation in vitro and ex vivo.International ophthalmology · 2023Article
- Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.Pharmaceutics · 2023Review
- Ethosomal Gel for Topical Administration of Dimethyl Fumarate in the Treatment of HSV-1 Infections.International journal of molecular sciences · 2023Article
- Promising Role of Silk-Based Biomaterials for Ocular-Based Drug Delivery and Tissue Engineering.Polymers · 2022Review
- Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye.Pharmaceutics · 2022Review
- Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.Pharmaceutics · 2021Review
- Partitioning and Spatial Distribution of Drugs in Ocular Surface Tissues.Pharmaceutics · 2021Article
- Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections.AAPS PharmSciTech · 2021Review
- The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic.Future microbiology · 2020Review
- Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD).Drug delivery and translational research · 2020Article
- Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers.Pharmaceutics · 2020Review
- In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis.Journal of nanobiotechnology · 2018Article
- Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.Pharmaceutics · 2018Review
- Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: development and simulation process in Wistar rats.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015Article
- Synthesis and Characterization of Ganciclovir Long Chain Lipid Prodrugs.Advances in ophthalmology & visual system · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ophthalmic liposomes of ganciclovir (GCV) were prepared by the reverse phase evaporation method, and their ocular pharmacokinetics in albino rabbits were compared with those obtained after dosing with GCV solution. The in vitro transcorneal permeability of GCV liposomes was found to be 3.9-fold higher than that of the solution. After in vivo instillation in albino rabbits, no difference was found in the precorneal elimination rate of GCV from liposome vs solution dosing. The aqueous humor concentration-time profiles of both liposomes and solution were well described by 2-compartmental pharmacokinetics with first-order absorption. The area under the curve of the aqueous humor concentration-time profiles of GCV liposomes was found to be 1.7-fold higher than that of GCV solution. Ocular tissue distribution of GCV from liposomes was 2 to 10 times higher in the sclera, cornea, iris, lens, and vitreous humor when compared with those observed after solution dosing. These results suggested that liposomes may hold some promise in ocular GCV delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.